Drugs / CKD-352
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04548427 | Sep 2020 → May 2021 | dry eye syndrome | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-352 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04548427 ↗ |
| Route | Other | “Eye Drop” NCT04548427 ↗ |